Who benefits most from semaglutide maintenance therapy?

Who loses the most weight and keeps it off?

People without type 2 diabetes consistently achieve the largest weight losses. In the landmark STEP 1 trial, 1961 adults with obesity or overweight (but no diabetes) lost an average of 14.9% of their body weight over 68 weeks on 2.4 mg semaglutide weekly—compared to just 2.4% with placebo [9]. More than half lost at least 15% of their starting weight [9]. A real-world clinic study confirmed this pattern: patients without diabetes lost 11.8% of their weight at 6 months, while those with diabetes lost only 7.2% [1].

Continuing the medication is critical for maintaining that loss. In the STEP 4 withdrawal trial, 803 people who had already lost 10.6% on semaglutide were randomized to stay on the drug or switch to placebo for 48 more weeks. Those who stayed on lost an additional 7.9% of their body weight; those who switched regained 6.9% [3]. The difference—nearly 15 percentage points—shows that maintenance therapy is essential for keeping weight off, not just for initial loss.

Adolescents also benefit substantially. In a trial of 201 teens aged 12–18 with obesity, semaglutide produced a 16.1% reduction in BMI over 68 weeks, while the placebo group saw a 0.6% increase [6]. This suggests that younger patients may respond even more robustly than adults, though the study was smaller.

Who benefits beyond the scale—heart, kidneys, and diabetes control?

People with established cardiovascular disease and overweight or obesity get a clear heart-protective effect. The SELECT trial, the largest study here with 17,604 participants, found that semaglutide reduced the risk of heart attack, stroke, or cardiovascular death by 20% over nearly 3.5 years, compared to placebo [4]. This benefit occurred in people without diabetes, meaning the protection is not just from blood sugar improvement.

For people with obesity-related heart failure with preserved ejection fraction (HFpEF), semaglutide dramatically improved symptoms and function. In a 52-week trial of 529 patients, those on semaglutide gained 7.8 more points on a heart failure symptom questionnaire (KCCQ-CSS), lost 13.3% of their body weight (vs. 2.6% on placebo), and walked 20.3 meters farther in 6 minutes [5]. Serious adverse events were half as common with semaglutide (13.3% vs. 26.7%) [5].

People with type 2 diabetes and poorly controlled blood sugar also benefit, though weight loss is more modest. In a real-world analysis of 2,311 patients with HbA1c ≥9%, those reaching the 1 mg maintenance dose saw a roughly 2.5% drop in HbA1c and delayed starting insulin by an average of 312 days [7]. Even patients on dialysis with obesity and diabetes improved: in a small study of 11 patients, HbA1c fell from 7.8% to 6.9%, and time-in-range (blood sugar 70–180 mg/dL) rose from 57% to 78% [10].

Kidney protection may also occur, partly independent of weight loss. Mediation analysis of two major trials (LEADER and SUSTAIN 6) found that about 25% of the kidney benefit (reduced albuminuria and kidney decline) was explained by blood sugar improvement, and 9–22% by blood pressure reduction, but weight loss played only a small role [11]. This suggests semaglutide may protect kidneys through direct mechanisms, not just through weight loss.

Who gets less benefit or needs to be cautious?

People with type 2 diabetes consistently lose less weight than those without diabetes. In the clinic study, patients with diabetes lost 7.2% at 6 months vs. 11.8% for those without [1]. Similarly, in the STEP 1 trial, which excluded diabetes, average weight loss was 14.9% [9], while in studies of people with diabetes, losses are typically 7–10% [2][7]. This is likely because diabetes itself alters metabolism and because some diabetes medications can promote weight gain.

Semaglutide is less effective than bariatric surgery for extreme weight loss and diabetes remission. A large real-world comparison of 45,093 patients found that only 3% of semaglutide users achieved both ≥20% weight loss and an HbA1c below 5.7% at one year, compared to 13.2% for tirzepatide and 24% for sleeve gastrectomy [2]. However, semaglutide had fewer emergency department visits and less need for new reflux or nausea medications than surgery [2].

Gastrointestinal side effects are common and can lead to stopping the drug. In the STEP 1 trial, 4.5% of semaglutide users discontinued due to nausea, diarrhea, or vomiting (vs. 0.8% on placebo) [9]. In the SELECT cardiovascular trial, 16.6% of semaglutide patients stopped the drug due to adverse events (vs. 8.2% on placebo) [4]. These are typically mild to moderate and transient, but they are real barriers for some people.

People who have already had bariatric surgery were excluded from most trials [1], so there is little evidence on whether semaglutide adds benefit after surgery. Similarly, data on people with severe kidney disease (not on dialysis) is limited, though the small dialysis study showed safety and efficacy [10].

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2021 to 2026, 3 from 2024 or later, 7 in Q1 journals, collectively cited 9,191 times — selected as the most relevant from 14 studies that passed quality screening, drawn from 64 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions